Coherus Bio (CHRS) Stock Price, Quote & News

Company Profile

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigat...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 649 3530

Website: www.coherus.com

Address:

333 Twin Dolphin Drive, Suite 600, Redwood City, United States

Jstocks33 Nov. 14 at 11:12 PM

$CHRS 30% down in a month a stock that has remained undervalued in many regards, with no particular concerns or news. Disappointing performance and management remains unbothered

1 · Reply

Jack_Nicholson_Truth Nov. 14 at 10:57 PM

$CHRS chrs had 5 ssr days out of the past 10. Lanfear hopefully has a pr to stop the bleeding

0 · Reply

cjwashington Nov. 14 at 9:29 PM

$CHRS what a drop, but expected, get in on lower price and just hang on for rhe next pr, just roll with the bull

0 · Reply

BigDaddyCapital Nov. 14 at 5:06 PM

$CHRS we need to buy at the ask above the bid.

0 · Reply

Sarandon Nov. 14 at 5:04 PM

$CHRS 💰💰💰 – Q3 2025 ending cash, cash equivalents and marketable securities of $191.7 million - LOQTORZI® net revenue was $11.2 million, a 12% increase over Q2 2025 - CHS-114, a highly selective Treg depleter, clinical program expanded to include colorectal cancer

0 · Reply

Sarandon Nov. 14 at 5:02 PM

$CHRS - CHS-114 demonstrated robust and selective depletion of CCR8+ Tregs as well as favorable immune remodeling in tumor tissue from head and neck squamous cell carcinoma (HNSCC) patients - CHS-114 administration resulted in selective depletion of CCR8+ Tregs and a >50% increase in intratumoral CD8 T cells – turning tumors “hot”

0 · Reply

Reydiy Nov. 14 at 4:05 PM

$CHRS make sure to close that daily back above 1.25 or 1.26

0 · Reply

Sarandon Nov. 14 at 3:54 PM

$CHRS has a market cap of $157 million and $192 million in cash 💰🚀👀

0 · Reply

Sarandon Nov. 14 at 3:19 PM

$CHRS Will we be the next ones to be bought? 🤔💰💰💰💰

0 · Reply

Reydiy Nov. 14 at 2:44 PM

$CHRS wow SPY pulling everything down with it even small caps..

0 · Reply

Coherus Oncology, Inc. (CHRS) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 7, 2025, 5:56 PM EST - 7 days ago

Coherus Oncology, Inc. (CHRS) Q3 2025 Earnings Call Transcript

Nov 7, 2025, 9:00 AM EST - 7 days ago

Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody

Nov 6, 2025, 4:14 PM EST - 8 days ago

Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 6, 2025, 1:54 PM EST - 8 days ago

Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer

Oct 30, 2025, 8:30 AM EDT - 15 days ago

Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 23, 2025, 8:30 AM EDT - 22 days ago

Coherus Oncology to Participate in Upcoming Investor Conferences

Oct 10, 2025, 4:32 AM EDT - 5 weeks ago

4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals

ALDX ALEC BDTX

Oct 3, 2025, 9:05 AM EDT - 6 weeks ago

Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Oct 1, 2025, 5:02 PM EDT - 6 weeks ago

Coherus Oncology, Inc. (CHRS) Presents at UBS Virtual Oncology Day Transcript

Oct 1, 2025, 10:43 AM EDT - 6 weeks ago

Coherus Oncology: Five Readouts Or More Possible In 2026

Aug 25, 2025, 4:55 PM EDT - 2 months ago

Coherus Oncology: On The Shaping Up

Aug 9, 2025, 11:35 AM EDT - 3 months ago

Coherus Oncology, Inc. (CHRS) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:41 PM EDT - 3 months ago

Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 4:45 PM EDT - 3 months ago

Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

May 12, 2025, 10:46 PM EDT - 6 months ago

Coherus BioSciences, Inc. (CHRS) Q1 2025 Earnings Call Transcript

May 12, 2025, 4:15 PM EDT - 6 months ago

Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

May 5, 2025, 4:01 PM EDT - 6 months ago

Coherus to Report First Quarter 2025 Financial Results on May 12, 2025

May 1, 2025, 5:04 PM EDT - 7 months ago

Coherus to Participate in Upcoming Investor Conferences

Apr 28, 2025, 10:10 AM EDT - 7 months ago

Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025

Apr 17, 2025, 5:53 AM EDT - 7 months ago

Coherus BioSciences: Cleaning The Balance Sheet And Developing New Drugs

Apr 14, 2025, 8:00 AM EDT - 7 months ago

Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise

Mar 25, 2025, 4:30 PM EDT - 8 months ago

Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 10, 2025, 8:52 PM EDT - 8 months ago

Coherus BioSciences, Inc. (CHRS) Q4 2024 Earnings Call Transcript

Mar 10, 2025, 4:12 PM EDT - 8 months ago

Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update

Mar 3, 2025, 8:30 AM EST - 9 months ago

Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025

Feb 24, 2025, 9:08 AM EST - 9 months ago

Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference

Dec 18, 2024, 8:30 AM EST - 11 months ago

Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

Dec 16, 2024, 6:08 PM EST - 11 months ago

Coherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing Development

Dec 3, 2024, 9:34 AM EST - 1 year ago

Why Is Coherus BioSciences Stock Trading Higher On Tuesday?

Nov 27, 2024, 4:01 PM EST - 1 year ago

Coherus Management to Participate in the 2024 Citi Global Healthcare Conference

Nov 6, 2024, 11:09 PM EST - 1 year ago

Coherus BioSciences, Inc. (CHRS) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:01 PM EST - 1 year ago

Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 30, 2024, 4:20 PM EDT - 1 year ago

Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024

Aug 13, 2024, 10:01 AM EDT - 1 year ago

Evaluating Coherus BioSciences: Udenyca's Success And Loqtorzi's Prospects

Aug 9, 2024, 6:08 PM EDT - 1 year ago

Coherus BioSciences, Inc. (CHRS) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 9:00 AM EDT - 1 year ago

Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024

Jun 27, 2024, 8:26 AM EDT - 1 year ago

Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction

May 31, 2024, 12:04 PM EDT - 1 year ago

Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway

May 30, 2024, 9:00 AM EDT - 1 year ago

Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference

May 23, 2024, 5:51 PM EDT - 1 year ago

Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 23, 2024, 9:00 AM EDT - 1 year ago

Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA

May 10, 2024, 12:07 AM EDT - 1 year ago

Coherus BioSciences, Inc. (CHRS) Q1 2024 Earnings Call Transcript

May 9, 2024, 4:01 PM EDT - 1 year ago

Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 7:30 AM EDT - 1 year ago

Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan

May 8, 2024, 9:00 AM EDT - 1 year ago

Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer

May 1, 2024, 4:30 PM EDT - 1 year ago

Coherus to Report First Quarter 2024 Financial Results on May 9, 2024

Apr 24, 2024, 10:02 AM EDT - 1 year ago

Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 8, 2024, 8:30 AM EDT - 1 year ago

Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting

Mar 20, 2024, 8:14 PM EDT - 1 year ago

Coherus Biosciences: Dumping One Drug But Showing Promise With Another

Jstocks33 Nov. 14 at 11:12 PM

$CHRS 30% down in a month a stock that has remained undervalued in many regards, with no particular concerns or news. Disappointing performance and management remains unbothered

1 · Reply

Jack_Nicholson_Truth Nov. 14 at 10:57 PM

$CHRS chrs had 5 ssr days out of the past 10. Lanfear hopefully has a pr to stop the bleeding

0 · Reply

cjwashington Nov. 14 at 9:29 PM

$CHRS what a drop, but expected, get in on lower price and just hang on for rhe next pr, just roll with the bull

0 · Reply

BigDaddyCapital Nov. 14 at 5:06 PM

$CHRS we need to buy at the ask above the bid.

0 · Reply

Sarandon Nov. 14 at 5:04 PM

0 · Reply

Sarandon Nov. 14 at 5:02 PM

0 · Reply

Reydiy Nov. 14 at 4:05 PM

$CHRS make sure to close that daily back above 1.25 or 1.26

0 · Reply

Sarandon Nov. 14 at 3:54 PM

$CHRS has a market cap of $157 million and $192 million in cash 💰🚀👀

0 · Reply

Sarandon Nov. 14 at 3:19 PM

$CHRS Will we be the next ones to be bought? 🤔💰💰💰💰

0 · Reply

Reydiy Nov. 14 at 2:44 PM

$CHRS wow SPY pulling everything down with it even small caps..

0 · Reply

Epic_dude0 Nov. 14 at 2:39 PM

$CHRS jeez, AWFUL premarket good bounceback

1 · Reply

Jack_Nicholson_Truth Nov. 14 at 2:37 PM

$CHRS good news is chrs touched every moving average including the 200 day. So all the tech traders can say it RETESTED EVERY SINGLE MOVING AVERAGE AND PRICE LEVEL.

1 · Reply

whateverhappenedthere Nov. 14 at 2:32 PM

$CHRS Deals and Data but forgot to mention Dilution. Down 95% from the Tori announcement, oh well.

0 · Reply

BMWLTWM3 Nov. 14 at 2:30 PM

$CHRS what BS..!

0 · Reply

Franciscomaligno Nov. 14 at 2:23 PM

$CHRS memorandum for myself and who wants to follow this. When you own shares of stocks like this , with very weak prospective plan , selling the only golden stone they had (udenyca) , don't believe to those clown predicting $4/5 . I should have sold this when was $1,80 , with a 60% profit , today , after just a month , i'll be red again. I'm a complete idiot !!!

5 · Reply

Jack_Nicholson_Truth Nov. 14 at 2:06 PM

$CHRS mm on full attack...$1.89 to 1.08 in two weeks. Earnings wasn't even bad Penny stocks do whatever the f they want. Now chrs back to trading 60-70% cash

0 · Reply

Sarandon Nov. 14 at 2:06 PM

$CHRS Jefferies Global Healthcare Conference in London, England on Tuesday, November 18, 2025, at 10:30 a.m. Greenwich Mean Time / 5:30 a.m. Eastern Time

0 · Reply

Jack_Nicholson_Truth Nov. 14 at 1:45 PM

$CHRS one of the mm going for max fear on the s3. Lower the price and less chance Lanfear can use it without bk

0 · Reply

Grandgustav Nov. 14 at 1:16 PM

$CHRS

2 · Reply

Sarandon Nov. 14 at 12:31 PM

🟢 On Thursday, Day One Biopharmaceuticals acquired Mersana Therapeutics ($MRSN) in a deal worth up to $285 million... 💰 🟢 Today, Friday, Merk ($MERK.X) acquired Cidara Therapeutics ($CDTX) for $9.2 billion.💰 🙋 Will Coherus ($CHRS) be next? It's undervalued, cheap, and has plenty of cash...🤔

0 · Reply

Jalu06 Nov. 14 at 12:13 PM

$CHRS interesting: Second IIT for the bms CCR8 compound in pancreatic adenocarcinoma https://clinicaltrials.gov/study/NCT07226856#more-information

1 · Reply

BigDaddyCapital Nov. 14 at 1:56 AM

$CHRS actually… this is not that bad. Neutral, I thought they already used it. It’s the same shelf offering from 2022 they just renewed it to have a safety blanket of $150M… doesn’t mean they will use but just in case. My guess is they might be submitting sBLA in near future on LOQ and once approval thy have to pay Junshi a reg payment, so they may use this

2 · Reply

Market Cap	90.31M
Revenue (ttm)	266.96M
Net Income (ttm)	28.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	10.68%
Debt to Equity Ratio	-0.20

Volume	1,822,400
Avg Vol	1,708,078
Day's Range	N/A - N/A
Shares Out	115.93M
Stochastic %K	30%
Beta	1.01
Analysts	Strong Sell
Price Target	$5.26